PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer is a phase 3, randomised interventional study registered as NCT07277842 by Sun Yat-sen University, with a registry enrolment figure of 382 participants, started 2025-12-29 and due to reach its primary completion in 2028-12-29. Interventions recorded: Serplulimab; FOLFOXIRI chemotherapy; CAPOX chemotherapy; Long-course pelvic radiotherapy. Conditions listed: Locally Advanced Low Rectal Adenocarcinoma; pMMR (Microsatellite Stable Rectal Cancer). Primary outcome: 3-year Event-Free Survival (EFS). Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.